Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer
作者： Fairooz Kabbinavar , Herbert I. Hurwitz , Louis Fehrenbacher , Neal J. Meropol , William F. Novotny
关键词:
摘要: Purpose: This phase II trial investigated the safety and efficacy of two doses bevacizumab, a monoclonal antibody to vascular endothelial growth factor, plus fluorouracil (FU)/leucovorin (LV) versus FU/LV alone in patients with metastatic colorectal cancer. Patients Methods: One hundred four previously untreated measurable cancer were randomly assigned one following three treatment groups: 36 FU (500 mg/m2)/LV mg/m2) alone, 35 + low-dose bevacizumab (5 mg/kg every 2 weeks), 33 high-dose (10 weeks). was given weekly for first 6 weeks each 8-week cycle. Results: Compared control arm, (at both dose levels) resulted higher response rates (control 17%, 95% confidence interval [CI], 7% 34%; 40%, CI, 24% 58%; 24%, 12% 43%), longer median time disease progression 5....
jco.org参考文章(30)
Robert Radinsky, Lee M. Ellis, Molecular Determinants in the Biology of Liver Metastasis Surgical Oncology Clinics of North America. ,vol. 5, pp. 215- 229 ,(1996) , 10.1016/S1055-3207(18)30378-8
Corazon D. Bucana, Yasuhiko Kitadai, Karen R. Cleary, Lee M. Ellis, Yutaka Takahashi, Expression of Vascular Endothelial Growth Factor and Its Receptor, KDR, Correlates with Vascularity, Metastasis, and Proliferation of Human Colon Cancer Cancer Research. ,vol. 55, pp. 3964- 3968 ,(1995)
Mark N Levine, Prevention of thrombotic disorders in cancer patients undergoing chemotherapy. Thrombosis and Haemostasis. ,vol. 78, pp. 133- 136 ,(1997) , 10.1055/S-0038-1657515
K. Margolin, M. S. Gordon, E. Holmgren, J. Gaudreault, W. Novotny, G. Fyfe, D. Adelman, S. Stalter, J. Breed, Phase Ib Trial of Intravenous Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor in Combination With Chemotherapy in Patients With Advanced Cancer: Pharmacologic and Long-Term Safety Data Journal of Clinical Oncology. ,vol. 19, pp. 851- 856 ,(2001) , 10.1200/JCO.2001.19.3.851
W K Evans, D W Nixon, J M Daly, S S Ellenberg, L Gardner, E Wolfe, F A Shepherd, R Feld, R Gralla, S Fine, A randomized study of oral nutritional support versus ad lib nutritional intake during chemotherapy for advanced colorectal and non-small-cell lung cancer. Journal of Clinical Oncology. ,vol. 5, pp. 113- 124 ,(1987) , 10.1200/JCO.1987.5.1.113
T Tokunaga, Y Oshika, Y Abe, Y Ozeki, S Sadahiro, H Kijima, T Tsuchida, H Yamazaki, Y Ueyama, N Tamaoki, M Nakamura, Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer British Journal of Cancer. ,vol. 77, pp. 998- 1002 ,(1998) , 10.1038/BJC.1998.164
Robert E. Frank, Theodore J. Saclarides, Sue Leurgans, Nicholas J. Speziale, Elizabeth A. Drab, David B. Rubin, Tumor angiogenesis as a predictor of recurrence and survival in patients with node-negative colon cancer. Annals of Surgery. ,vol. 222, pp. 695- 699 ,(1995) , 10.1097/00000658-199512000-00002
Napoleone Ferrara, Terri Davis-Smyth, THE BIOLOGY OF VASCULAR ENDOTHELIAL GROWTH FACTOR Endocrine Reviews. ,vol. 18, pp. 4- 25 ,(1997) , 10.1210/EDRV.18.1.0287
Maria Koch, Thomas A. McPherson, Ronald D. Egedahl, Effect of sex and reproductive history on the survival of patients with colorectal cancer Journal of Chronic Diseases. ,vol. 35, pp. 69- 72 ,(1982) , 10.1016/0021-9681(82)90032-7
Yuji Takebayashi, Shin-ichi Akiyama, Kazutaka Yamada, Suminori Akiba, Takashi Aikou, Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma Cancer. ,vol. 78, pp. 226- 231 ,(1996) , 10.1002/(SICI)1097-0142(19960715)78:2<226::AID-CNCR6>3.0.CO;2-J